Sage Therapeutics Inc
(FRA:SG7)
€
5.452
0.102 (1.91%)
Market Cap: 325.18 Mil
Enterprise Value: -211.07 Mil
PE Ratio: 0
PB Ratio: 0.61
GF Score: 49/100 SAGE Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024 / 12:30AM GMT
Release Date Price:
€23.8
(+20.81%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst
Welcome, everyone, 42nd JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, [Malcolm Cloonan], Lauren Hall and Priyanka Grover. Our next presenting company is Sage Therapeutics. I'm presenting on behalf of the company, we have CEO, Barry Greene. Sorry, I was just a little flustered with that music, yeah so, my bad man that wasâ¦
Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director
Don't be flustered Anupam.
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst
Not great delivery.
Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director
And look, Anupam, thanks for having us, and I'd like to thank the organizers of JPMorgan for having us here today. It's great to be back with all of you in San Francisco, and it's not raining for those of you that that aren't here
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot